Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Wofsy

Showing results (11-20 of 60) with videos related to

Pageof 6
Sort By:
Annals of the Rheumatic Diseases|June 22, 2014
Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)David Isenberg, Caroline Gordon, Daiana Licu, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 9, 2016
Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRILCaroline Gordon, David Wofsy, Stephen Wax, et al.
Arthritis and Rheumatism|December 30, 2009
Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trialEllen M Ginzler, David Wofsy, David Isenberg, et al.
Arthritis and Rheumatism|December 17, 2002
Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trialKenneth C Kalunian, John C Davis, Joan T Merrill, et al.
Lupus Science & Medicine|December 8, 2017
Correlation of hypogammaglobulinaemia with proteinuria, and the relationship between hypogammaglobulinaemia and infection in active lupus nephritisDawn Elaine Smilek, Noha Lim, Linna Ding, et al.
Rheumatology Advances in Practice|September 19, 2019
Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programmeCaroline Gordon, Roberto Bassi, Peter Chang, et al.
Kidney International Reports|September 11, 2018
Limited Reliability of the Spot Urine Protein/Creatinine Ratio in the Longitudinal Evaluation of Patients With Lupus NephritisGanesh Shidham, Isabelle Ayoub, Dan Birmingham, et al.
Arthritis and Rheumatism|February 28, 2009
A quality indicator set for systemic lupus erythematosusJinoos Yazdany, Pantelis Panopalis, Joann Zell Gillis, et al.
Annals of the Rheumatic Diseases|March 23, 2018
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trialJoan T Merrill, William R Shanahan, Morton Scheinberg, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|March 22, 2018
Do Multiple Mini-Interview and Traditional Interview Scores Differ in Their Associations With Acceptance Offers Within and Across Five California Medical Schools?Anthony Jerant, Mark C Henderson, Erin Griffin, et al.
Pageof 6

Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
Annals of the Rheumatic Diseases|June 22, 2014
Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)David Isenberg, Caroline Gordon, Daiana Licu, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 9, 2016
Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRILCaroline Gordon, David Wofsy, Stephen Wax, et al.
Arthritis and Rheumatism|December 30, 2009
Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trialEllen M Ginzler, David Wofsy, David Isenberg, et al.
Arthritis and Rheumatism|December 17, 2002
Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trialKenneth C Kalunian, John C Davis, Joan T Merrill, et al.
Lupus Science & Medicine|December 8, 2017
Correlation of hypogammaglobulinaemia with proteinuria, and the relationship between hypogammaglobulinaemia and infection in active lupus nephritisDawn Elaine Smilek, Noha Lim, Linna Ding, et al.
Rheumatology Advances in Practice|September 19, 2019
Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programmeCaroline Gordon, Roberto Bassi, Peter Chang, et al.
Kidney International Reports|September 11, 2018
Limited Reliability of the Spot Urine Protein/Creatinine Ratio in the Longitudinal Evaluation of Patients With Lupus NephritisGanesh Shidham, Isabelle Ayoub, Dan Birmingham, et al.
Arthritis and Rheumatism|February 28, 2009
A quality indicator set for systemic lupus erythematosusJinoos Yazdany, Pantelis Panopalis, Joann Zell Gillis, et al.
Annals of the Rheumatic Diseases|March 23, 2018
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trialJoan T Merrill, William R Shanahan, Morton Scheinberg, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|March 22, 2018
Do Multiple Mini-Interview and Traditional Interview Scores Differ in Their Associations With Acceptance Offers Within and Across Five California Medical Schools?Anthony Jerant, Mark C Henderson, Erin Griffin, et al.
Pageof 6